Xeltis Strengthens Leadership with Luc Verhees Appointment Amid US Trial Launch
Portfolio - People | Nov 05, 2024 | Ysios Capital
Xeltis, a medtech company at the forefront of developing transformative implants for cardiovascular and vascular applications, has appointed Luc Verhees as Vice President of Clinical Business Development. This strategic leadership appointment comes at a significant moment as Xeltis recently secured an Investigational Device Exemption (IDE) from the FDA to commence a US pivotal study for aXess, its revolutionary vascular access conduit. Verhees brings over 30 years of expertise in cardiovascular clinical research and previously served with distinction at Xeltis as the Senior Vice President of Global Clinical Affairs. This move fortifies Xeltis' leadership fabric at a time when the US and EU are witnessing pivotal trials for aXess, reinforcing the company’s trajectory towards commercialization and exploring additional therapeutic indications. The appointment underscores Xeltis' commitment to innovation in hemodialysis access and cardiovascular therapy, as it aims to improve patient outcomes with its proprietary endogenous tissue restoration platform.
Sectors
- Medical Technology
- Clinical Research
Geography
- The Netherlands – Xeltis is based in The Netherlands and plays a significant role in its operations and development activities.
- United States – Xeltis has announced plans to initiate a US pivotal trial, underlining the United States' importance in the company's strategic roadmap.
Industry
- Medical Technology – Xeltis is involved in developing innovative medical implants, classifying it under the medical technology industry.
- Clinical Research – The article discusses pivotal trials and clinical development, which are key aspects of the clinical research sector.
Financials
- – No specific financial figures are provided in the article.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Xeltis | Company | Target | A medtech company pioneering in transformative vascular and cardiovascular implants. |
| Luc Verhees | Person | New Appointee | Appointed VP of Clinical Business Development at Xeltis, bringing extensive experience in cardiovascular clinical research. |
| Ysios Capital | Company | PE Firm | One of the investors backing Xeltis, participating in its funding and growth journey. |
| US Food and Drug Administration (FDA) | Government | Regulatory Authority | Approved the IDE for Xeltis’s US pivotal trial for aXess. |